#Lembaz
Laut Hersteller ist Lembaz das erste Mittel, das bei der schwersten, früh beginnenden Form der Niemann-Pick-Krankheit Typ C das Sterberisiko senkt.
FDA lässt Lembaz bei früher Niemann-Pick-Krankheit Typ C zu
Beren Therapeutics teilte am 17. November 2026 mit, dass die US-Arzneimittelbehörde FDA Lembaz (Adrabetadex) zugelassen hat, laut Hersteller das erste Mittel, das bei der früh beginnenden Form der Niemann-Pick-Krankheit Typ C das Überleben verbessert
denkstrom.org
November 18, 2026 at 4:16 PM
FDA Approves Lembaz for Infantile-Onset Niemann-Pick Type C, First Treatment Shown to Extend Survival

#fda #rare-disease #npc #drug-approval
FDA Approves Lembaz for Infantile-Onset Niemann-Pick Type C, First Treatment Shown to Extend Survival
FDA approves Lembaz (adrabetadex) for infantile-onset Niemann-Pick type C — the first therapy shown to extend survival in this ultra-rare childhood disorder.
agentictribune.com
November 17, 2026 at 7:40 PM
November 17, 2026 at 8:58 PM
The #FDA has approved #Beren 's #Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
Beren's Niemann-Pick drug Lembaz cleared by FDA
The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
pharmaphorum.com
November 18, 2026 at 3:11 PM
In 2018, this drug seemed done, as its trial came up short and production stopped.

Today, the FDA approved Beren Therapeutics’ Lembaz as the first drug shown to help kids with severe Niemann-Pick type C live longer.

Thanks to years of family effort, kids get more birthdays.

#RareDisease #Pharma
November 18, 2026 at 4:10 PM
The U.S. Food and Drug Administration on Tuesday cleared Lembaz (adrabetadex) injection, the first therapy shown to help people with a severe form of Niemann-Pick disease type C live longer, according to the agency.

#Health
FDA approves Lembaz, first NPC drug to extend survival
The FDA approved Lembaz (adrabetadex) injection to reduce the risk of death in infantile-onset Niemann-Pick disease type C, according to the agency.
unitedstatestribune.com
November 17, 2026 at 8:36 PM
For infants with Niemann Pick type C, there was no approved drug. Now there is one, and it cut the risk of death by 55 percent. FDA approves Lembaz as first drug shown to extend survival in infantile onset Niemann Pick type C
November 18, 2026 at 6:27 PM
The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C, a rare and fatal genetic disorder.
https://www.medpagetoday.com/genetics/generalgenetics/123945
FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder
Adrabetadex-treated patients with Niemann-Pick disease type C lived longer than external controls
www.medpagetoday.com
November 18, 2026 at 4:56 PM